Clinical trial
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
NCT04364763 is registered in ClinicalTrials.gov with Renibus Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
- Lead sponsor
- Renibus Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 5, 2020
- Completion date
- September 30, 2021
- Enrollment
- 42 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.